|
1
|
Minato H, Kurose N, Fukushima M, Nojima T,
Usuda K, Sagawa M, Sakuma T, Ooi A, Matsumoto I, Oda M, et al:
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA,
CD146, and desmin for distinguishing malignant mesothelioma from
reactive mesothelial cells. Am J Clin Pathol. 141:85–93. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hata Y, et al: Journal of Clinical and
Experimental Medicine. 251(351–356): 423–435. 2014.(In
Japanese).
|
|
3
|
Bueno R, Stawiski EW, Goldstein LD,
Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS,
Chirieac LR, et al: Comprehensive genomic analysis of malignant
pleural mesothelioma identifies recurrent mutations, gene fusions
and splicing alterations. Nat Genet. 48:407–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takeda M, Kasai T, Enomoto Y, Takano M,
Morita K, Kadota E and Nonomura A: 9p21 Deletion in the diagnosis
of malignant mesothelioma, using fluorescence in situ hybridization
analysis. Pathol Int. 60:395–399. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sheffield BS, Hwang HC, Lee AF, Thompson
K, Rodriguez S, Tse CH, Gown AM and Churg A: BAP1
immunohistochemistry and p16 FISH to separate benign from malignant
mesothelial proliferations. Am J Surg Pathol. 39:977–982. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sekido Y: Molecular pathogenesis of
malignant mesothelioma. Carcinogenesis. 34:1413–1419. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yokoyama T, Osada H, Murakami H, Tatematsu
Y, Taniguchi T, Kondo Y, Yatabe Y, Hasegawa Y, Shimokata K, Horio
Y, et al: YAP1 is involved in mesothelioma development and
negatively regulated by Merlin through phosphorylation.
Carcinogenesis. 29:2139–2146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murakami H, Mizuno T, Taniguchi T, Fujii
M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et
al: LATS2 is a tumor suppressor gene of malignant mesothelioma.
Cancer Res. 71:873–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cong W, Hirose T, Harita Y, Yamashita A,
Mizuno K, Hirano H and Ohno S: ASPP2 regulates epithelial cell
polarity through the PAR complex. Curr Biol. 1408–1414. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu CY, Lv X, Li T, Xu Y, Zhou X, Zhao S,
Xiong Y, Lei QY and Guan KL: PP1 cooperates with ASPP2 to
dephosphorylate and activate TAZ. J Biol Chem. 286:5558–5566. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grannas K, Arngården L, Lönn P,
Mazurkiewicz M, Blokzijl A, Zieba A and Söderberg O: Crosstalk
between Hippo and TGFb: Subcellular localization of YAP/TAZ/Smad
complexes. J Mol Biol. 427:3407–3415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wells CD, Fawcett JP, Traweger A, Yamanaka
Y, Goudreault M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, et
al: A Rich1/Amot Complex Regulates the Cdc42 GTPase and
apical-polarity proteins in epithelial cells. Cell. 125:535–548.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO Classification of Tumours of the Lung,
Pleura, Thymus and Heart. 4th edition. WHO, Geneva: pp. 154–171.
2015
|
|
14
|
Yue G, Sun X, Gimenez-Capitan A, Shen J,
Yu L, Teixido C, Guan W, Rosell R, Liu B and Wei J: TAZ is highly
expressed in gastric signet ring cell carcinoma. Biomed Res Int.
2014:3930642014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chiosea S, Krasinskas A, Cagle PT,
Mitchell KA, Zander DS and Dacic S: Diagnostic importance of 9p21
homozygous deletion in malignant mesithliomas. Mod Pathol.
21:742–747. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hwang HC, Sheffield BS, Rodriguez S,
Thompson K, Tse CH, Gown AM and Churg A: Utility of BAP1
immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of
malignant mesothelioma in effusion cytology specimens. Am J Surg
Pathol. 40:120–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altomare DA, Vaslet CA, Skele KL, De
Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB and Testa
JR: A mouse model recapitulating molecular features of human
mesothelioma. Cancer Res. 65:8090–8095. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujii M, Toyoda T, Nakanishi H, Yatabe Y,
Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al:
TGF-b synergizes with defects in the Hippo pathway to stimulate
human malignant mesothelioma growth. J Exp Med. 209:479–494. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu
ZH, Xu F and Zhao HY: Prognostic significance of TAZ expression in
resected non-small cell lung cancer. J Thorac Oncol. 7:799–807.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li PD, Wang XJ, Shan Q, Wu YH and Wang Z:
Evaluation of TAZ expression and its effect on tumor invasion and
metastasis in human glioma. Asian Pac J Trop Med. 7:757–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Illei PB, Rusch VW, Zakowski MF and
Ladanyi M: Homozygous deletion of CDKN2A and codeletion of the
methylthioadenosine phosphorylase gene in the majority of pleural
mesotheliomas. Clin Cancer Res. 9:2108–2113. 2003.PubMed/NCBI
|
|
23
|
Singhi AD, Krasinskas AM, Choudry HA,
Bartlett DL, Pingpank JF, Zeh HJ, Luvison A, Fuhrer K, Bahary N,
Seethala RR and Dacic S: The prognostic significance of BAP1, NF2,
and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol.
29:14–24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carbone M, Shimizu D, Napolitano A, Tanji
M, Pass HI, Yang H and Pastorino S: Positive nuclear BAP1
immunostaining helps differentiate non-small cell lung carcinomas
from malignant mesothelioma. Oncotarget. 7:59314–59321. 2016.
View Article : Google Scholar : PubMed/NCBI
|
